Mon, Apr 14, 6:11 PM (35 days ago)
**Lexaria Bioscience Corp. (LEXX) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $357,923 (up 21.5% YoY from $296,278) - **IP Licensing:** $348,000 (up 19.9% YoY) - **B2B:** $9,923 (up 81.3% YoY) - **Gross Profit:** $355,203 (up 21.9% YoY) - **Operating Expenses:** $5,796,922 (up 177.7% YoY) - **R&D:** $3,639,136 (up 345.5% YoY) - **General & Admin:** $2,157,786 (up 70.0% YoY) - **Net Loss:** $5,423,600 (up 195.3% YoY) - **Cash Flow from Operations:** -$4,223,936 (vs. -$1,801,267 YoY) - **Cash Flow from Financing:** $4,357,113 (vs. $5,272,206 YoY) - **Cash Position:** $6,468,934 (down 0.5% from $6,499,885) **Profit Margins:** - **Gross Margin:** 99.2% (vs. 98.4% YoY) - **Operating Margin:** -1542.4% (vs. -610.3% YoY) - **Net Margin:** -1515.6% (vs. -619.9% YoY) **Key Trends & Uncertainties:** - Significant increase in R&D and G&A expenses due to clinical trials and strategic hires. - Substantial doubt about the company's ability to continue as a going concern within one year. - Dependence on equity financing to fund operations and clinical trials. - Uncertainty around the success and timing of clinical trials and regulatory approvals. **Future Operations Impact:** - Continued focus on DehydraTECH technology and GLP-1/GIP drug formulations. - Plans to advance clinical trials and seek strategic partnerships or collaborations. - Need for additional equity financing to support operations and clinical development. **Ticker:** LEXX **Exchange:** NASDAQ Capital Market